Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
| العنوان: | Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy |
|---|---|
| المؤلفون: | Nicola Personeni, ChiehJu Lee, Anushi Bulumulle, Anwaar Saeed, Abdul Rafeh Naqash, Petros Fessas, Tomi Jun, Musharraf Navaid, Bo Yu, Celina Ang, Yinghong Wang, Hannah Hildebrand, Ahmed Kaseb, David J. Pinato, Jingky Lozano-kuehne, Tiziana Pressiani, Dominik Bettinger, David Szafron, Thomas U. Marron, Lorenza Rimassa, Mahvish Muzaffar, Yehia I. Abugabal, Sirish Dharmapuri, Uqba Khan, Sonal Paul, Yi Hsiang Huang, Neil Nimkar |
| المصدر: | Journal for Immunotherapy of Cancer Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020) |
| بيانات النشر: | BMJ Publishing Group, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Male, Cancer Research, medicine.medical_specialty, 2019-20 coronavirus outbreak, Poor prognosis, Carcinoma, Hepatocellular, Immune checkpoint inhibitors, Immunology, Short Report, immunomodulation, 03 medical and health sciences, 0302 clinical medicine, Overall response rate, Prednisone, Adrenal Cortex Hormones, Internal medicine, medicine, Immunology and Allergy, Humans, Prospective Studies, Adverse effect, Immune Checkpoint Inhibitors, RC254-282, Pharmacology, Science & Technology, liver neoplasms, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, 3. Good health, 030104 developmental biology, Treatment Outcome, Corticosteroid therapy, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Molecular Medicine, Female, ADVERSE EVENTS, business, Life Sciences & Biomedicine, medicine.drug |
| الوصف: | The impact of corticosteroid therapy (CT) on efficacy of immune checkpoint inhibitors (ICI) is undefined in hepatocellular carcinoma (HCC). We evaluated whether CT administered at baseline (bCT) or concurrently with ICI (cCT) influences overall (OS), progression-free survival (PFS) and overall response rates (ORR) in 341 patients collected across 3 continents. Of 304 eligible patients, 78 (26%) received >10 mg prednisone equivalent daily either as bCT (n=14, 5%) or cCT (n=64, 21%). Indications for CT included procedure/prophylaxis (n=37, 47%), management of immune-related adverse event (n=27, 35%), cancer-related symptoms (n=8, 10%) or comorbidities (n=6, 8%). Neither overall CT, bCT nor cCT predicted for worse OS, PFS nor ORR in univariable and multivariable analyses (p>0.05). CT for cancer-related indications predicted for shorter PFS (p |
| اللغة: | English |
| تدمد: | 2051-1426 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5ea12367e000bff0d4273d97fed2df5Test http://europepmc.org/articles/PMC7542664Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....b5ea12367e000bff0d4273d97fed2df5 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20511426 |
|---|